You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MGMT methylation

Showing 1 - 25 of 645
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

O6-methylguanine-DNA Methyltransferase Promoter Methylation and

Active, not recruiting
  • Sarcoma
  • O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and MGMT expression on dacarbazine treated sarcoma patients
  • Naples, Campania, Italy
    National Cancer Institute of Naples
May 14, 2021

Glioblastoma, Adult Trial in Germany (APG101, Alectinib, Idasanutlin)

Recruiting
  • Glioblastoma, Adult
  • Berlin, Germany
  • +12 more
May 20, 2022

Colorectal Tumors, Microsatellite Instability Trial in Milano, Rozzano (temozolomide (induction),, pembrolizumab (treatment))

Recruiting
  • Colorectal Neoplasms
  • Microsatellite Instability
  • temozolomide (induction),
  • pembrolizumab (treatment)
  • Milano, Italy
  • +3 more
Sep 28, 2022

Glioblastoma Multiforme Trial in United States (PPX (CT2103), Temozolomide)

Completed
Has Results
  • Glioblastoma Multiforme
  • La Jolla, California
  • +8 more
Feb 13, 2020

Neuroendocrine Tumors Trial in France (Oxaliplatin-based chemo, Alkylating-based chemo)

Active, not recruiting
  • Neuroendocrine Tumors
  • Oxaliplatin-based chemotherapy
  • Alkylating-based chemotherapy
  • Amiens, France
  • +18 more
Mar 15, 2022

Advanced Glioblastoma, Metastatic Melanoma in the CNS, MGMT-Unmethylated Glioblastoma Trial in Ramat Gan (Crizanlizumab-Tmca 10

Not yet recruiting
  • Advanced Glioblastoma
  • +2 more
  • Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO]
  • Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO]
  • Ramat Gan, Israel
    Sheba medical center
Jun 11, 2023

Metastatic Colorectal Cancer Trial in Milan (Bevacizumab, Irinotecan, Leucovorin)

Recruiting
  • Metastatic Colorectal Cancer
  • Milan, Italy
    Fondazione IRCCS Istituto Nazionale dei Tumori
Apr 1, 2022

Rectal Cancer Trial in Milan (External-beam radiation, Capecitabine, Temozolomide)

Recruiting
  • Rectal Cancer
  • External-beam radiation
  • +2 more
  • Milan, Italy
    Fondazione IRCCS Istituto Nazionale dei Tumori
Jan 25, 2022

Glioma, Malignant Trial in Rom, Rome (histopathological analysis; morphological and non-morphological magnetic resonance)

Completed
  • Glioma, Malignant
  • histopathological analysis; morphological and non-morphological magnetic resonance
  • Rom, Roma, Italy
  • +1 more
Mar 28, 2023

Glioblastoma Multiforme Trial in Calgary, Edmonton (Biomarker based treatment (Temozolomide monotherapy or Radiotherapy

Recruiting
  • Glioblastoma Multiforme
  • Biomarker based treatment (Temozolomide monotherapy or Radiotherapy monotherapy)
  • Chemo-Radiotherapy consisting of 40 Gy in 15 daily fractions with concurrent temozolomide.
  • Calgary, Alberta, Canada
  • +1 more
Jun 24, 2022

Metastatic Colorectal Cancer Trial in Milan (Temozolomide, Nivolumab, Ipilimumab)

Completed
  • Metastatic Colorectal Cancer
  • Milan, MI, Italy
    Fondazione IRCCS Istituto Nazionale dei Tumori
Apr 1, 2022

Colorectal Cancer Trial (Irinotecan, Temozolomide)

Not yet recruiting
  • Colorectal Cancer
  • (no location specified)
Apr 1, 2022

Colorectal Cancer Trial in New Haven (Temozolomide + Olaparib)

Active, not recruiting
  • Colorectal Cancer
  • Temozolomide + Olaparib
  • New Haven, Connecticut
    Yale New Haven Hospital
Aug 17, 2022

Glioma, Malignant Trial in United States (biological, drug, radiation, other)

Active, not recruiting
  • Glioma, Malignant
  • AdV-tk
  • +5 more
  • Los Angeles, California
  • +7 more
Jan 30, 2023

Glioblastoma Multiforme, Glioblastoma Multiforme, Adult, Supratentorial Glioblastoma Trial in Bethesda, Cleveland (biological,

Not yet recruiting
  • Glioblastoma Multiforme
  • +3 more
  • P140K-MGMT
  • +5 more
  • Bethesda, Maryland
  • +1 more
Jul 4, 2022

Glioblastoma Multiforme, Adult Trial (Integrated boost technique (SIB) guided by PET FDOPA)

Not yet recruiting
  • Glioblastoma Multiforme, Adult
  • Integrated boost technique (SIB) guided by PET FDOPA
  • (no location specified)
Dec 7, 2022

Gliosarcoma, MGMT-Unmethylated Glioblastoma Trial in United States (biological, device, other, radiation, drug)

Suspended
  • Gliosarcoma
  • MGMT-Unmethylated Glioblastoma
  • Ipilimumab
  • +6 more
  • Birmingham, Alabama
  • +285 more
Aug 24, 2022

Grade IV Astrocytoma, Glioblastoma Trial in France (Temozolomide, folinic acid at pharmacological dose is the escalated drug,

Terminated
  • Grade IV Astrocytoma
  • Glioblastoma
  • Angers, France
  • +3 more
May 20, 2021

Glioma Trial in Zhengzhou (Histopathology images based prediction of molecular pathology)

Recruiting
  • Glioma
  • Histopathology images based prediction of molecular pathology
  • Zhengzhou, Henan, China
    Department of Neurosurgery, First Affiliated Hospital of Zhengzh
Feb 5, 2021

Glioma Trial in Zhengzhou (Prediction of molecular pathology)

Recruiting
  • Glioma
  • Prediction of molecular pathology
  • Zhengzhou, Henan, China
    Department of Neurosurgery, First Affiliated Hospital of Zhengzh
Feb 5, 2021

Glioblastoma Trial in Spain (Temozolomide)

Completed
Has Results
  • Glioblastoma
  • Badalona, Barcelona, Spain
  • +19 more
Dec 17, 2020

Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma

Active, not recruiting
  • Glioblastoma
    • Birmingham, Alabama
    • +18 more
    Mar 7, 2022

    Neuroendocrine Tumors, Frailty, Chemo Effect Trial in Milan (Temozolomide capsule)

    Recruiting
    • Neuroendocrine Tumors
    • +2 more
    • Temozolomide capsule
    • Milan, Italy
      European Institute of Oncology, IEO, IRCCS
    Sep 21, 2022

    Glioma, Glioblastoma, Glioblastoma Multiforme Trial in Houston (VAL-083, Dianhydrogalactitol)

    Active, not recruiting
    • Glioma
    • +4 more
    • VAL-083, Dianhydrogalactitol
    • Houston, Texas
      University of Texas MD Anderson Cancer Center
    Mar 23, 2022

    Glioblastoma, Gliosarcoma Trial in United States (drug, radiation, other)

    Recruiting
    • Glioblastoma
    • Gliosarcoma
    • Little Rock, Arkansas
    • +119 more
    Aug 11, 2022